Novotech CRO Announces Expansion into South Africa
Novotech has expanded its clinical services with a new office in Johannesburg, South Africa
Novotech, Australia’s largest clinical CRO with offices throughout Asia, has expanded its clinical services with a new office in Johannesburg, South Africa to accommodate increasing sponsor demand for quality clinical research management.
Novotech is an internationally recognized full service CRO known for its experience across 11 countries from Australia and New Zealand through Asia to India, Malaysia, the Philippines, Singapore, South Korea, Taiwan, Thailand and Hong Kong, and now South Africa.
Together with its partner in China, Novotech now provides biotechnology and pharmaceutical companies access to patients from a population base of over 3 billion people
As a leading regional CRO, Novotech has been actively involved in hundreds of drug development programs for US and EU registration over the past 18 years.
CEO Alek Safarian said the expansion to South Africa followed demand from existing USA-based biotechnology sponsors for whom Novotech was already managing clinical trial programs in the Asia Pacific.
“HIV and TB are serious health challenges in some South African patient populations, while metabolic diseases common in the USA and Australia such as diabetes, heart disease and hypertension are also on the increase.”
“As the leading market for clinical trials in Africa, there are currently over 1700 studies registered on the South African Department of Health online registry,” said Safarian
http://www.sanctr.gov.za/SAClinicalbrnbspTrials/tabid/169/Default.aspx
“This expansion into a new territory for us is in keeping with our broader strategy of covering emerging markets for our clients. We have been managing trials in South Africa for three years through consultants already, and this experience will put us in good stead for this new operation to make a strong contribution to the group.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
